SCHEMBL2403256

SCHEMBL2403256

CN(CCCNC1=CC(=O)c2nc(-c3cccc(Cl)c3)oc2C1=O)CCCNC1=CC(=O)c2nc(-c3cccc(Cl)c3)oc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.52
CDC25B P30305 1/20 0.52
CDC25C P30307 1/20 0.52
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
HPGD P15428 3/20 0.48
HSD17B10 Q99714 2/20 0.48
S100A4 P26447 1/20 0.39
RAD52 P43351 1/20 0.39
MAOB P27338 2/20 0.35
ALOX15 P16050 1/20 0.35
SLC9A1 P19634 1/20 0.35
MAPT P10636 2/20 0.35
KDR P35968 2/20 0.35
THRB P10828 1/20 0.35
NOTUM Q6P988 1/20 0.35
PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859017 0.90 CDC25A (0.63) CDC25ACDC25BCDC25CKDM4EALDH1A1
SCHEMBL2401747 0.88 CDC25A (0.49) CDC25ACDC25BCDC25CKDM4EALDH1A1
SCHEMBL2401252 0.82 CDC25A (0.57) CDC25ACDC25BCDC25CALDH1A1S100A4
SCHEMBL2398596 0.82 CDC25A (0.50) CDC25ACDC25BCDC25CKDM4EALDH1A1
SCHEMBL2398528 0.82 CDC25A (0.50) CDC25ACDC25BCDC25CKDM4EALDH1A1
SCHEMBL1918209 0.82 CDC25A (0.57) CDC25ACDC25BCDC25CKDM4EALDH1A1
SCHEMBL2404412 0.82 CDC25A (0.60) CDC25ACDC25BCDC25CKDM4EALDH1A1
SCHEMBL2400556 0.82 CDC25A (0.48) CDC25ACDC25BCDC25CKDM4EALDH1A1
SCHEMBL2401246 0.81 CDC25A (0.49) CDC25ACDC25BCDC25CKDM4EALDH1A1
SCHEMBL1919578 0.81 CDC25A (0.56) CDC25ACDC25BCDC25CKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US claimed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP claimed
US-8017637-B2 Inhibitors of cdc phosphatases IPSEN PHARMA S.A.S. (FR) 2011-09-13 US disclosed
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US disclosed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP disclosed
EP-1831209-A2 CDC25 PHOSPHATASE INHIBITORS Société de Conseils de Recherches et d'Applications Scientifiques SAS (S.C.R.A.S) (FR) 2007-09-12 EP disclosed
WO-2006067311-A2 CDC25 PHOSPHATASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) SAS (FR) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES CDC25C, CDC25A, CDC25B CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.